Financials in USD. Standardized financial statements.
A compact view of how TScan Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $10.32M | $2.82M | $21.05M | $13.54M | $10.14M | $1.08M | $0 |
| Revenue Growth? | +266.7% | -86.6% | +55.5% | +33.5% | +834.7% | 0.0% | 0.0% |
| Cost of Revenue? | $2.87M | $0 | $0 | $0 | $0 | $20.58M | $9.44M |
| Gross Profit? | $7.46M | $2.82M | $21.05M | $13.54M | $10.14M | -$19.49M | -$9.44M |
| Gross Margin? | +72.2% | +100.0% | +100.0% | +100.0% | +100.0% | -1796.5% | 0.0% |
| Operating Expenses? | $143.27M | $137.64M | $114.51M | $80.17M | $58.78M | $6.74M | $4.77M |
| Operating Income? | -$135.81M | -$134.82M | -$93.46M | -$66.64M | -$48.64M | -$26.23M | -$14.21M |
| EBITDA? | -$132.95M | -$119.74M | -$80.10M | -$59.91M | -$45.30M | -$25.00M | -$13.69M |
| Income Before Tax | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -$48.63M | -$26.13M | -$13.66M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -$48.63M | -$26.13M | -$13.66M |
| EPS? | $-1.00 | $-1.14 | $-1.36 | $-2.74 | $-2.03 | $-1.04 | $-0.53 |
| Diluted EPS? | $-1.00 | $-1.14 | $-1.36 | $-2.74 | $-2.03 | $-1.04 | $-0.53 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality